ORIGINAL RESEARCH ORIJINAL ARAŞTIRMA

DOI: 10.5336/medsci.2024-105399

# **Current Attitudes of Plastic Surgeons in Türkiye Regarding Breast Augmentation Surgery: A Descriptive Study**

Meme Büyütme Cerrahisinde Türkiye'deki Plastik Cerrahların Güncel Tutumları: Tanımlayıcı Çalışma

<sup>10</sup> Nurullah GÜNDÜZ<sup>a</sup>, <sup>10</sup> Alper ÖZTÜRK<sup>a</sup>, <sup>10</sup> Ayhan Işık ERDAL<sup>a</sup>, <sup>10</sup> Serhat ŞİBAR<sup>a</sup>

<sup>a</sup>Gazi University Faculty of Medicine, Department of Plastic, Reconstructive and Aesthetic Surgery, Ankara, Türkiye

ABSTRACT Objective: There are many nuances in each stage of breast augmentation surgery. In clinical practice, each plastic surgeon may have different preferences during different stages of the surgery. In this study, a survey was conducted to reveal the current attitudes of plastic surgeons in breast augmentation surgery. Material and Methods: A 35-item electronic survey was administered to plastic surgeons in Türkiye. The survey included questions about common surgical practices, the use of new technologies, and technical issues in secondary surgery. The collected data were systematically analyzed. Results: A total of 130 plastic surgeons participated in the survey. The preferred incision was inframammary in 95 percent of cases, periareolar in 3 percent, and transaxillary in 1 percent. The most frequently preferred pocket plane was the submuscular plane in 63 percent of cases and the subglandular or subfascial plane in 37 percent. Ninety-three percent of the participants stated that they always preferred silicone implants. Seventy percent of the participants used textured implants more frequently than smooth-surfaced implants. Eighty-three percent of the participants did not use an insertion funnel. Forty percent of the participants mostly used implants with a volume of 300-350 cc, and 31% of them mostly used implants with a volume of 275-325 cc. Conclusion: This study revealed that there is a trend toward more frequent use of inframammary incisions, silicone as the filling material, textured surfaces, and implant volumes larger than 275 cc in Türkiye. The authors think that complications that may arise in the long term could be different due to different preferences among countries.

Keywords: Breast implants; breast implantation; mammaplasty

ÖZET Amac: Meme büyütme cerrahisi, her aşamasında çeşitli incelikler içermektedir. Plastik cerrahlar, genellikle prosedürün farklı aşamalarında bireysel tercihler sergilemektedir. Bu çalışma, plastik cerrahların meme büyütme cerrahisiyle ilgili mevcut eğilimlerini ve uygulamalarını araştırmayı amaçlamaktadır. Gereç ve Yöntemler: Türkiye genelindeki plastik cerrahlara 35 maddelik elektronik bir anket uygulanmıştır. Anket, yaygın cerrahi uygulamalar, yeni teknolojilerin kullanımı ve sekonder cerrahide teknik konuları icermektedir. Toplanan veriler sistematik bir şekilde analiz edilmiştir. Bulgular: Anketi yanıtlayan 130 plastik cerrahın %95'i inframammarian insizyonu tercih ederken, %3'ü periareolar insizyonu ve %1'i transaksiller insizyonu tercih etmektedir. En çok tercih edilen cep kas altı olup %63 oranında kullanılırken, %37 oranında subglandüler veya subfasiyal düzey tercih edilmiştir. Katılımcıların %93'ü genellikle silikon implantları tercih ettiklerini belirtmiştir. Katılımcıların %70'i pürtüklü yüzey implantları, düz yüzeyli implantlardan daha sık kullanmaktadır. Kullanıcıların %83'ü yerleştirme hunisi kullanmamaktadır. Katılımcıların %40'ı genellikle 300-350 cc hacmindeki implantları, %31'i ise 275-325 cc hacmindeki implantları tercih etmektedir. Sonuç: Bu çalışma, Türk plastik cerrahlarının inframammarian insizyonu, silikon implantları, pürtüklü yüzey implantları ve 275 cc üzeri hacmindeki implantları daha sık tercih ettiklerini göstermektedir. Yazarlar, farklı ülkelerde uygulanan tekniklerin ve tercihlerin uzun vadeli komplikasyonlar üzerinde etkili olabileceğini düşünmektedir.

Anahtar Kelimeler: Meme implantları; meme implantasyonu; mammoplasti

Breast augmentation is one of the most commonly performed surgical procedures worldwide.<sup>1,2</sup> This operation is carried out using various surgical techniques and implant options to achieve aesthetic goals. The first attempts at breast augmentation date back to the late 1800s. In 1895, Czerny used a lipoma

TO CITE THIS ARTICLE: Gündüz N, Öztürk A, Erdal AI, Şibar S. Current attitudes of plastic surgeons in Türkiye regarding breast augmentation surgery: A descriptive study. Turkiye Klinikleri J Med Sci. 2025;45(2):56-65.



taken from a patient's back to augment the breast.<sup>3</sup> In 1961, Cronin and Gerow developed the first silicone prosthesis.<sup>4</sup> These implants are known as the first-generation implants. The implants used in current practice are 5<sup>th</sup>-generation implants.<sup>5</sup> With the development of implants, breast augmentation surgery has become increasingly popular, leading to more successful surgical outcomes. However, the increasing number of cases has also led to a significant rise in the number of complications.<sup>6,7</sup>

While there is a consensus on some surgical principles, many issues are still controversial. Plastic surgeons have different options regarding the choice of incision, implant characteristics, pocket plane, postoperative care, and complication management. Recent additions to these options include three-dimensional imaging, autologous fat grafting, acellular dermal matrix, and funnel use.<sup>8-11</sup> Surgeons can customize all these options based on their patients' needs and their own surgical experience.

There is no comprehensive and up-to-date study on the attitudes of plastic surgeons towards breast augmentation in Türkiye. In this study, a survey study was conducted to reveal in detail the practices of Turkish plastic surgeons in breast augmentation surgery.

## MATERIAL AND METHODS

A 35-item survey developed by Hidalgo and Sinno was translated into Turkish and sent as an electronic survey to plastic surgeons in Türkiye via email groups.<sup>12</sup> The survey was created using Google Forms (Google, Mountain View, CA, USA). It began in May 2024 and was completed in June 2024. The survey included questions on the site of incision, length of incision, implant characteristics, surface type, complication management, and other details in breast augmentation surgery. Participants were kept anonymous and informed about the purpose of the survey. Ethical committee approval is not required for such studies. The guiding principles of the Helsinki Declaration were followed. The survey results were analyzed using standard methods. No statistical analysis methods were used. The 35-item survey is included in Appendix 1.

APPENDIX 1: 35-item Questionnaire	
1. How many years have you been practicing as a plastic su	rgeon?
• 0-5	
• 0-10 • 11-15	
• 16-20	
• 21-25	
• 25	
2. What is your work setting?	
Solo practice     Solo practice within a shared clinic	
Small plastic surgery team (2-5 surgeons)	
<ul> <li>Large plastic surgery team (≥6 surgeons)</li> </ul>	
Other (multidisciplinary group, academic, military)	
3. How many primary breast augmentation surgeries do you	perform annually?
• 1-50 • 51-150	
• 151-250	
• 251-350	
• 350	
4. For what purpose do you use breast implants?	
• 25% cosmetic, 75% reconstructive	
50% cosmetic, 50% reconstructive	
75% cosmetic, 25% reconstructive	
100% cosmetic	
<ul> <li>How frequently do you use anatomical implants?</li> <li>I do not use anatomical implants</li> </ul>	
I use anatomical implants less than 50% of the time	
• I use anatomical implants in about half of the cases	
• I use anatomical implants more than 50% of the time	
I use anatomical implants in all cases	
6. What are your concerns regarding anatomical implants?	
(You can select more than one)	
No concerns	
Concerned about lack of proven aesthetic superiority	
Concerned about risk of mairotation     Concerned about surface texturing	
(e.g., late seroma, anaplastic large cell lymphoma)	
Concerned about limited incision options	
Concerned about the need for a longer incision	
Concerned about high cost	
<ul> <li>Other (please specify)</li> <li>How frequently do you use autologous fat for primary brea</li> </ul>	ast augmentation?
• Never	
Use autologous fat less than 50% of the time	
Use autologous fat in about half of the cases	
Use autologous fat more than 50% of the time	
8. What are your concerns regarding the use of autologous t	fat in primary breast
augmentation? (You can select more than one)	Sector primary Diedol
No concerns	
Concerned about it being a complex procedure	
Concerned about limited augmentation capacity	
Concerned about potential donor site deformity     Concerned about the need for multiple autologous for a	raffing proceduros
Concerned about the need for multiple autologous fat g	raning procedures
Other (please specify)	
9. How frequently do you use autologous fat as an adjunct te	echnique?
(With the primary technique)	
Never	0% of the time
Use autologous fat as an adjunct technique less than 5	If of the cases
Use autologous fat as an adjunct technique more than	50% of the time
Use autologous fat as an adjunct technique in all cases	
10.Have you encountered a case of ALCL in your clinical pra	actice?
• Yes	
• INU	

APPENDIX 1: 35-item Questionnaire (contunied).	APPENDIX 1: 35-item Questionnaire (contunied).
11.Would you perform breast augmentation on a patient with heterozygous factor V	22.What size are the implants you use?
Leiden mutation?	• <250 cc
Yes, without any preventive measures	• 250-300 cc
Yes, with compression devices and anticoagulation/chemoprophylaxis	• 275-325 cc
Yes, with compression devices and postoperative ultrasonography	• 300-350 cc
• NO 12 Do you utilize 2 dimensional imaging technology for prespective planning?	• 350 cc
<ul> <li>Yoc</li> </ul>	23. Which company's implants do you use? (You can select more than one)
• No	Allergan
13. If yes, what is the role of 3-dimensional imaging in your clinical practice?	• Wentor
Effective marketing tool	Polytoch
Effective educational tool	• Motiva
Effective sizing tool	Sientra
Complicates the consultation process	• Other
Not proven to be beneficial in terms of cost and effort	24.What is the most common incision you use?
• Other	• Axillary
14.Do you use acellular dermal matrix (ADM) in secondary cases?	Periareolar
• No	Inframammary
15 If yes, for what purposes do you use ADM?	Periumbilical
Capsular contracture	25.What is the most common pocket plane you use?
Contour deformity	Complete submuscular
Capsular support suture	Partial submuscular
Rippling or thin skin flaps	Subgrandular     Subfracial
Other	Sublascial     26 De you use antihistic prophylavic2 (You can select more than one)
16.How often do you use a funnel (insertion device) when placing an implant?	Intravenous antibiotics during anesthesia induction
Never	Irrigation with povidone-iodine only
Use a funnel less than 50% of the time	Irrigation with povidone-iodine and bacitracin (Bacitracin Zinc. Pharm-RX Chemical
Use a funnel when placing a large implant through a small incision	Corp., ABD) or neomycin (Neomycin Sulfate, Medimetriks Pharmaceuticals, Inc., ABD)
Use a funnel more than 50% of the time	Irrigation with classic triple antibiotics
Generally use a funnel	Other types of irrigation
17.If you do not use a funnel, what are your reasons for not using it?	<ul> <li>Postoperative oral antibiotic therapy</li> </ul>
(You can select more than one)	Do not use antibiotic prophylaxis
Additional cost	27.Do you recommend postoperative massage to your patients?
Additional procedural step	• Yes
Not applicable for form-stable implants     Detential to domage the implant's outer layer	• NO
Do not believe it is necessary	• 1 day
18.Do you use adhesive plastic material for implant protection before placement?	• 1 week
[e.g., Tegaderm (3M, St. Paul, Minn.), Op-Site (Smith & Nephew, London, UK),	• 2-3 weeks
loban (3M)]	• 4 weeks
<ul> <li>Only on the nipple-areola complex</li> </ul>	6 weeks
Only on the incision	8-12 weeks
<ul> <li>On both the nipple-areola complex and the incision</li> </ul>	29.Do you use pharmacological agents for capsular contracture in your clinical
• Do not use	practice?
19.What method do you use for implant size selection?	Yes, as prophylaxis in all cases
(You can select more than one)	Yes, only at the initial signs of capsular contracture
Sizing with round silicone implants     Sizing with silicone forms	tes, as the first treatment approach for established contracture     No
Sizing with since bags or other methods	30 Are pharmacological agents effective in preventing/reducing capsular
Sizing with mathematical measurements	contracture?
Sizing with imaging methods	• Yes
• None	Only effective if used early
20.What is the filling material of the implants you use?	Not sure
100% silicone	• No
Mostly silicone/sometimes saline	31. Which non-surgical methods do you use for treating capsular contracture?
• Use both equally	(You can select more than one)
Mostly saline/sometimes silicone	Leukotriene inhibitors     Descuering //Descuering //OL Color illes Consultus Tisses(A.O. T. L. )
100% Saline     21 What is the surface type of the implacts you use?	<ul> <li>Papaverine (Papaverin HUL, Galen Ilaç Sanayi ve Ticaret A.Ş., Turkey)</li> <li>Cox 2 inhibitors</li> </ul>
<ul> <li>100% smooth surface</li> </ul>	• External ultrasound
Mostly smooth/sometimes textured	Electromagnetic field therapies
Use both equally	Massage
Mostly textured/sometimes smooth	Closed capsulotomy
100% textured	• None
Polyurethane surface	• Other

Polyurethane surface

<b>APPENDIX 1:</b> 35-item Questionnaire (contunied).
<ul> <li>32.Apart from hematoma and infection, what is the most common reason for reoperation?</li> <li>Capsular contracture</li> <li>Implant malposition</li> <li>Implant failure</li> <li>Seroma</li> <li>Size change</li> </ul>
<ul> <li>33.What surgical technique do you use for managing capsular contracture?</li> <li>Anterior capsulectomy</li> <li>Total capsulectomy</li> <li>Capsulectomy and coverage with ADM</li> <li>Creating a new pocket</li> <li>Creating a new pocket and coverage with ADM</li> </ul>
<ul> <li>34. What is the most frequently used technique for managing recurrent capsular contracture in patients with subpectoral (dual plane) implants?</li> <li>Anterior capsulectomy</li> <li>Total capsulectomy</li> <li>Capsulectomy and coverage with ADM</li> <li>Creating a new pocket</li> <li>Creating a new pocket and coverage with ADM</li> <li>I do not perform surgical treatment in the presence of bilateral capsular contracture and asymmetry</li> <li>I recommend implant removal</li> </ul>
<ul> <li>35.What method do you most frequently use in the treatment of double-bubble and bottoming-out?</li> <li>Percutaneous suture or external support when the onset is early</li> <li>Capsulorrhaphy only</li> <li>Capsulorrhaphy with ADM support</li> <li>Removal and later reimplantation of the implant</li> <li>Removal of the implant and switching to a different type of implant</li> <li>Reformation of the inframammary fold</li> </ul>

# RESULTS

A total of 130 responses were received. Because the response rate was 18.13 percent, it was concluded that the participation was low compared to the survey conducted by Hidalgo and Sinno with members of the American Society of Plastic Surgeons.<sup>12</sup>

## CURRENT DISCUSSIONS

One-third of participants never use anatomical implants, while half use them in less than half of the cases (48.1%). The 3 most common concerns about anatomical implants are the potential for malrotation (41.1%), the lack of proven aesthetic superiority compared to round implants (22.5%), and the high cost (18.6%) (Table 1).

The use of autologous fat as a primary breast augmentation technique is preferred by approximately half of the participants (53.1%). However, the majority of those who use autologous fat stated that they use it in less than 50 percent of cases. The most

Performation% of del respondentionNever9.5< 50%48.1Haif the time10.9>50%6.2Aways5.4No concerns22.5Assthetic result not proven superior22.5Marotation problem (late seroma, ALCL)10.1Texturization problem (late seroma, ALCL)10.1Larger incision3.9Larger incision4.7Ibiger cost18.6Other7.0Vorter4.6So%6.6Adays0.8Softwall19.6No concerns25.5Marotation potential4.16Ibiger cost3.9Ibiger cost3.9Softwall10.4Adays0.8Softwall10.4Adays0.8Concerns25.6No concerns25.6Ibiger cost to complex10.4Ibiger cost to complex <th colspan="3">TABLE 1: Current controversies</th>	TABLE 1: Current controversies		
Use anatomical implants         29.5           <50%         48.1           Half the time         10.9           >50%         6.2           Always         5.4           Concerns regarding anatomical implants (can select more than one)         No concerns           No concerns         22.5           Aesthetic result not proven superior         22.5           Malrotation potential         41.1           Texturization problem (late seroma, ALCL)         10.1           Limited incision option         3.9           Larger incision         4.7           Higher cost         18.6           Other         7           Use of autologous fat for primary augmentation         3.9           Never         46.9           <50%         1.6           Always         0.8           Concerns regarding autologous fat as a primary technique         (can select more than one)           No concerns         25.6           Process too complex         10.4           Limited augmentation potential         41.6           Potential donor-site deformity         9.6           May require multiple fat-grafting procedures         23.2           Cost         8	Controversy	% of total respondents	
Never29.5<50%	Use anatomical implants		
<50%	Never	29.5	
Half the time10.9>50%6.2Always5.4Concerns regarding anatomical implants (can select more than one)No concernsNo concerns22.5Aesthetic result not proven superior22.5Malrotation potential41.1Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentation3.9+Aif the time3.9>50%1.6Always0.8Concerns regarding autologous fat as a primary technique(can select more than one)0.4No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental techniqueNever26.2<50%	<50%	48.1	
>50%6.2Always5.4Concerns regarding anatomical implants (can select more than one)No concernsNo concerns22.5Aesthetic result not proven superior22.5Malrotation potential41.1Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentation3.9+aff the time3.9>50%1.6Always0.8Concerns regarding autologous fat as a primary technique(can select more than one)0.4No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental techniqueNever26.2<50%	Half the time	10.9	
Always5.4Concerms regarding anatomical implants (can select more than one)No concerms22.5No concerms22.5Aesthetic result not proven superior22.5Malrotation potential41.1Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentation4.7Never46.9<50%	>50%	6.2	
Concerns regarding anatomical implants (can select more than one)No concerns22.5Aesthetic result not proven superior22.5Malrotation potential41.1Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentation4.6.9<50%	Always	5.4	
No concerns22.5Aesthetic result not proven superior22.5Malrotation potential41.1Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentationNever46.9<50%	Concerns regarding anatomical implants (can sele	ct more than one)	
Aesthetic result not proven superior22.5Malrotation potential41.1Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentationNever46.9<50%	No concerns	22.5	
Malrotation potential41.1Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentationNever46.9<50%	Aesthetic result not proven superior	22.5	
Texturization problem (late seroma, ALCL)10.1Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentationNever46.9<50%	Malrotation potential	41.1	
Limited incision option3.9Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentation7Never46.9<50%	Texturization problem (late seroma, ALCL)	10.1	
Larger incision4.7Higher cost18.6Other7Use of autologous fat for primary augmentation7Never46.9<50%	Limited incision option	3.9	
Higher cost18.6Other7Use of autologous fat for primary augmentation46.9Never46.946.946.9Half the time3.9>50%1.6Always0.8Concerns regarding autologous fat as a primary technique(can select more than one)No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique16.1Never26.2<50%	Larger incision	4.7	
Other7Use of autologous fat for primary augmentationNever46.9Never46.946.9Half the time3.9>50%1.60.8Concerns regarding autologous fat as a primary technique (can select more than one)0.8No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental techniqueNever26.2<50%	Higher cost	18.6	
Use of autologous fat for primary augmentation       46.9         <50%	Other	7	
Never46.9<50%	Use of autologous fat for primary augmentation		
<50%	Never	46.9	
Half the time3.9>50%1.6Always0.8Concerns regarding autologous fat as a primary technique (can select more than one)25.6No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique5.6>50%6.1Half the time5.6>50%6.3Always0.8Seen a case of ALCL in your practiceYesYes, no special precautions beyond SCDs14.8Yes, with anticoagulation/chemoprophylaxis and SCDs48.4	<50%	46.9	
>50%1.6Always0.8Concerns regarding autologous fat as a primary technique (can select more than one)25.6No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique15.2Never26.2<50%	Half the time	3.9	
Always0.8Concerns regarding autologous fat as a primary technique (can select more than one)25.6No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental techniqueNever26.2<50%	>50%	1.6	
Concerns regarding autologous fat as a primary technique         (can select more than one)         No concerns       25.6         Process too complex       10.4         Limited augmentation potential       41.6         Potential donor-site deformity       9.6         May require multiple fat-grafting procedures       23.2         Cost       8         Other       15.2         Use of autologous fat as a supplemental technique       6.2         <50%	Always	0.8	
No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique26.2<50%	Concerns regarding autologous fat as a primary te	chnique	
No concerns25.6Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique15.2Vever26.2<50%	(can select more than one)		
Process too complex10.4Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental techniqueNever26.2<50%	No concerns	25.6	
Limited augmentation potential41.6Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique15.2Vever26.2<50%	Process too complex	10.4	
Potential donor-site deformity9.6May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique26.2<50%	Limited augmentation potential	41.6	
May require multiple fat-grafting procedures23.2Cost8Other15.2Use of autologous fat as a supplemental technique15.2Never26.2<50%	Potential donor-site deformity	9.6	
Cost8Other15.2Use of autologous fat as a supplemental techniqueNever26.2<50%	May require multiple fat-grafting procedures	23.2	
Other15.2Use of autologous fat as a supplemental techniqueNever26.2<50%	Cost	8	
Use of autologous fat as a supplemental technique         Never       26.2         <50%	Other	15.2	
Never26.2<50%	Use of autologous fat as a supplemental technique	)	
<50%	Never	26.2	
Half the time5.6>50%6.3Always0.8Seen a case of ALCL in your practiceYesYes1.6No98.4Whether or not to operate on a heterozygous factor V Leider patientYes, no special precautions beyond SCDsYes, with anticoagulation/chemoprophylaxis and SCDs48.4	<50%	61.1	
>50%       6.3         Always       0.8         Seen a case of ALCL in your practice       1.6         Yes       1.6         No       98.4         Whether or not to operate on a heterozygous factor V Leiden patient       Yes, no special precautions beyond SCDs         Yes, with anticoagulation/chemoprophylaxis and SCDs       48.4	Half the time	5.6	
Always       0.8         Seen a case of ALCL in your practice       1.6         Yes       1.6         No       98.4         Whether or not to operate on a heterozygous factor V Leiden patient       Yes, no special precautions beyond SCDs       14.8         Yes, with anticoagulation/chemoprophylaxis and SCDs       48.4	>50%	6.3	
Seen a case of ALCL in your practice         Yes       1.6         No       98.4         Whether or not to operate on a heterozygous factor V Leiden patient         Yes, no special precautions beyond SCDs       14.8         Yes, with anticoagulation/chemoprophylaxis and SCDs       48.4	Always	0.8	
Yes     1.6       No     98.4       Whether or not to operate on a heterozygous factor V Leiden patient       Yes, no special precautions beyond SCDs     14.8       Yes, with anticoagulation/chemoprophylaxis and SCDs     48.4	Seen a case of ALCL in your practice		
No     98.4       Whether or not to operate on a heterozygous factor V Leiden patient       Yes, no special precautions beyond SCDs     14.8       Yes, with anticoagulation/chemoprophylaxis and SCDs     48.4	Yes	1.6	
Whether or not to operate on a heterozygous factor V Leiden patient         Yes, no special precautions beyond SCDs       14.8         Yes, with anticoagulation/chemoprophylaxis and SCDs       48.4	No	98.4	
Yes, no special precautions beyond SCDs 14.8 Yes, with anticoagulation/chemoprophylaxis and SCDs 48.4	Whether or not to operate on a heterozygous facto	r V Leiden patient	
Yes, with anticoagulation/chemoprophylaxis and SCDs 48.4	Yes, no special precautions beyond SCDs	14.8	
· · · · ·	Yes, with anticoagulation/chemoprophylaxis ar	nd SCDs 48.4	
Yes, with SCDs and postoperative ultrasound 1.6	Yes, with SCDs and postoperative ultrasound	1.6	
No 35.2	No	35.2	

ALCL: Anaplastic large cell lymphoma; SCDs: Sequential compression devices

common concerns about this method are the limited augmentation potential (41.6%) and the potential need for multiple fat-grafting procedures (23.2%). Seventy-four percent of the participants use autologous fat grafting as a supplemental technique with implants. However, the majority of those who use autologous fat grafting as a supplemental technique stated that they use it in less than 50 percent of cases (Table 1).

One point six percent of the participants had seen a case of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Regarding deep vein thrombosis, another matter of concern, about 1-3 of the participants prefer not to perform breast augmentation on patients with heterozygous factor V Leiden mutation, while the participants who perform surgery prefer to use compression devices at a minimum. Less than half of the participants (48.4%) consider adding anticoagulation/chemoprophylaxis as a preventive measure (Table 1).

## NEW TECHNOLOGIES

Most participants (82.8%) do not use 3-dimensional imaging in their current practice. According to the participants who utilize 3-dimensional imaging technologies, the most important advantages are that it is an effective sizing tool (31.7%), an effective educational tool (22%), and an effective marketing tool (12.2%) (Table 2).

Approximately 13 percent of the participants use acellular dermal matrix in secondary cases. According to the participants who use the acellular dermal matrix in secondary cases, the indications for its use are capsulorrhaphy buttress (26.9%), and ripples or thin tissues (30.8%) (Table 2).

Eighty-three and a half percent of the participants do not use an insertion funnel for implant placement, while only 2.4 percent always use it. Among the participants who do not use a funnel, 50.9 percent cite the additional cost, and 56.2 percent do not find it necessary (Table 2).

Approximately half of the participants do not use adhesive sheeting for skin protection before implant placement. The majority of the remaining participants (34.4%) use adhesive plastic material only to cover the nipple-areola complex, and the rest use it to cover both the nipple-areola complex and the incision (Table 2).

TABLE 2: New technologies		
Characteristic % of to	otal respondents	
Use of 3-dimensional imaging technology		
Yes	17.2	
No	82.8	
If yes, assess the role of 3-dimensional imaging in your pr	actice	
It is an effective marketing tool	12.2	
It is an effective educational tool	22	
It is an effective sizing tool	31.7	
It has made the consultation process overly complex	4.9	
It has not proven worth the cost and effort	17.1	
Other	12.2	
Use of ADM in secondary cases		
Yes	13.2	
No	86.8	
If yes, for what purposes?		
Capsular contracture	7.7	
Contour deformities	7.7	
Capsulorrhaphy buttress	26.9	
Ripples or thin tissues	30.8	
Other	26.9	
Use of insertion funnels	00.5	
Never	83.5	
	9.4	
	1.0	
>50%	3.1	
Always	2.4	
Future cost	50.0	
Extra cost	50.9 21.0	
Adds extra step	21.9	
	4.4	
Not pecessary	4.4 56 1	
Lise of adhesive plastic sheeting for skip protection before	50.1	
implant insertion [e.g. Tegaderm (3M_St_Paul_Minn.)		
On-Site (Smith & Nenhew London United Kingdom) Joha	an (3M)]	
Yes over the nipple-areola complex	34.4	
Yes over the incision	7	
Yes, over both nipple-areola complex and the incision	11 7	
No, I do not use it	46.9	

ADM: Acellular dermal matrix

## COMMON PRACTICES

Most of the participants use mathematical methods (44.2%), round silicone implants (36.4%), or silicone forms (20.9%) for preoperative sizing. Approximately 10 percent of the participants (10%) use imaging methods. Ninety-three percent of the participants (93%) use only silicone implants. The surface of the

implant is either always textured (37.5%) or mostly textured and sometimes smooth (32.8%). The most common volume ranges are 300-350 cc (40%) and 275-325 cc (31.2%). The most commonly used implant brand is Mentor (Santa Barbara, California, USA) (80.6%). The most frequently used incision is the inframammary (95.3%). The partial submuscular pocket is the most commonly preferred tissue plane (51.6%), followed by the subfascial pocket (30%) (Table 3).

Seventy-two percent of the participants use intravenous antibiotics during anesthesia induction, and 48.8% use postoperative antibiotics. Irrigation with triple antibiotics is performed by 31.8% of the participants. Thirty-nine percent of the participants use povidone-iodine irrigation with or without additional antibiotics. None of the participants reported not using antibiotic prophylaxis. Approximately half of the participants (49.2%) use postoperative massage. Physical activity restriction was recommended for 2-3 weeks (38.8%). In the non-surgical treatment of capsular contracture, about half of the participants (42.4%) prefer massage. Pharmacological agents such as leukotriene inhibitors, papaverine (Papaverin HCL, Galen İlaç Sanayi ve Ticaret A.Ş., Turkey), Cox-2 inhibitors are not preferred by the majority of the participants (85.3%) (Table 3).

## TECHNICAL CONSIDERATIONS IN SECONDARY PROCEDURES

Apart from hematoma and infection, the most common reasons for reoperation are size changes (38.2%) and capsular contracture (26.8%), and implant malposition (21%). First-time capsular contracture is most commonly treated with total capsulectomy (45.7%), followed by new pocket creation (24%) and anterior capsulectomy (23.3%). In patients with subpectoral (dual-plane) implants, recurrent contracture is most commonly treated with total capsulectomy (30.5%), and new pocket creation (26.6%). The most common treatment method for double-bubble deformity or bottomingout is recreating the inframammary fold (59.2%), followed by implant removal and switching to another type (12.8%) and isolated capsulorrhaphy (11.2%) (Table 4).

TABLE 3:         Common practice	es
Characteristic	% of total respondents
Method for implant selection (can select more than one) Sizing using round silicone implants	36.4
Sizing with silicone forms "Rice baos" or other as preoperative sizes	20.9
"High-five" or other tissue-based system	44.2
Imaging technology None	9.3 13.2
Implant filler type used 100% silicone	93
Mostly silicone/some saline	3.1
Equal use Mostly saline/some silicone	1.6 2.3
100% saline Implant shell surface type used	0
100% smooth	7
Equal use	15.6 7
Mostly textured/some smooth 100% textured	32.8 37.5
Polyuretan	0
<250 cc	4
250–300 cc 275–325 cc	16.8 31.2
300–350 cc	40 ×
Implant manufacturer use (can select more than one)	0
Allergan Mentor	5.4 80.6
Nagor Polytech	15.5 37.2
Motiva	25.6
Sientra Other	0.8 17.8
Most common incision Axillary	1.6
Periareolar	3.1
Periumbilical	95.3
Most common pocket location Complete submuscular	11.7
Partial submuscular	51.6
Subfascial	30.5
Use of antibiotic prophylaxis (can select more than one) Intravenous antibiotics at induction of anesthesia	72.1
Povidone-iodine (only) irrigation Povidone-iodine/bacitracin or neomycin irrigation	15.5 23.3
Classic triple-antibiotic irrigation	31.8
Postoperative oral antibiotics	23.3 48.8
Never use antibiotic prophylaxis Use of postoperative massage	0
Yes	49.2
Recommendation for return to unrestricted activities	JU.Ö
1 day 1 week	1.6 9.3
2-3 week 4 month	38.8 31 8
6 month	14
8-12 month Use of pharmacologic agents for capsular contracture	4.7
Yes, prophylactically in all Yes, only at first sign of onset	3.9 9 3
Yes, as first option in established contracture	1.6
Are they effective in reducing capsular contracture	85.3
Yes Only if started early	4.7 9.4
Not sure	65.6
Nonsurgical methods for treating capsular contracture (can select r	20.3 more than one)
Leukotriene inhibitors Papaverine	8 4
Cox-2 inhibitors	5.6
Pulsed electromagnetic field therapy	2.4
Massage Closed capsulotomy	42.4 7.2
None Other	46.4 3.2
0.00	0.2

# DEMOGRAPHIC CHARACTERISTICS OF THE PARTICIPANTS AND CLINICAL PRACTICE

When the specialization durations of the participants were examined across six groups based on 5-year time intervals, it was observed that approximately  $2^{nd}$ - $3^{rd}$  (61.6%) had less than 15 years of experience. The most common practice type is solo practice (59.7%). Approximately half (48.8%) of the participants use breast implants solely for cosmetic purposes, while the majority of the remaining participants preferred to use them for both cosmetic and reconstructive purposes. The majority of the participant (58.5%) performs fewer than 50 breast augmentation surgeries per year (Table 5).

TABLE 4: Technical considerations in secondary procedures	
Characteristic	% of total respondents
Most common reasons for reoperation beyond hematom	a or infection
Capsular contracture	26.8
Implant malposition	21.1
Implant failure	9.8
Seroma	4.1
Size change	38.2
Surgical technique most commonly used for capsular con	ntracture
Anterior capsulectomy	23.3
Total capsulectomy	45.7
Capsulectomy with ADM lining	4.7
Neopocket formation	24
Neopocket with ADM lining	2.3
Most common technique for treating recurrent capsular of	contracture in
patients with subpectoral (dual-plane) implants	
Anterior capsulectomy	9.4
Total capsulectomy	30.5
Capsulectomy with ADM pocket lining	6.3
Neopocket formation	26.6
Neopocket formation with ADM pocket lining	6.3
No surgical treatment if bilateral capsular contracture	e 2.3
and symmetric	
No surgery and consider removing implants	18.8
Most common treatment for double-bubble or bottoming-	out
Percutaneous suture or external support for early on	set 7.2
Capsulorrhaphy alone	11.2
Capsulorrhaphy with ADM buttress	2.4
Remove implants and replace later	7.2
Remove implant and transition to a different implant	12.8
Reconstruction of the inframammary fold	59.2

ADM: Acelluler dermal matrix

TABLE 5: Demographics and practice patterns	
Characteristic	% of total respondents
Years in practice	
0-5 years	20.8
6-10 years	20.8
11-15 years	20
16-20 years	13.1
21-25 years	14.6
>25 years	10.8
Type of practice	
Solo	59.7
Solo practice-shared facility	13.2
Small plastic surgery group (2-5 surgeons)	8.5
Large plastic surgery practice (≥6 surgeons)	9.3
Other (multispecialty group, academic, military	) 9.3
Annual number of primary augmentations	
1-50	58.5
51-150	30.8
151-250	6.9
251-350	3.8
>350	0
Nature of practice	
100% reconstructive	0.8
25% cosmetic, 75% reconstructive	10.9
50% cosmetic, 50% reconstructive	10.1
75% cosmetic, 25% reconstructive	29.5
100% cosmetic	48.8

## DISCUSSION

The advancements in breast augmentation surgery have created many options for both patients and plastic surgeons.<sup>13,14</sup> One of the most critical steps in breast augmentation surgery is determining the shape of the implant.<sup>15</sup> Although anatomical implants are widely used in current practice, many surgeons have concerns about anatomical implants.<sup>16</sup> In this survey, the most common concerns among surgeons who do not use anatomical implants are the potential for malrotation and the lack of proven aesthetic superiority of anatomical implants compared to round implants. A literature review indicates that anatomical implants do not have a proven aesthetic advantage over round implants.<sup>5,13,15</sup>

Approximately 10% of the participants are concerned about the complications that are specific to textured surfaces. The fact that only 1.6% of the participants have seen a case of BIA-ALCL is consistent with the presence of only four cases diagnosed with BIA-ALCL in Türkiye until 2021.<sup>17</sup>

The use of autologous fat in primary breast augmentation is a controversial topic due to concerns about the safety and efficacy of the surgical technique.<sup>18</sup> Therefore, it is expected that half of the surgeons do not use autologous fat (46.9%) and the majority of the rest do so less than half of the time (46.9%). The two main concerns are the limited augmentation potential compared to implants and the potential need for multiple fat grafting procedures. The use of autologous fat grafting as a supplemental technique is considered more feasible by the participants.

Approximately 5 percent of the population carries the heterozygous factor V Leiden mutation, which is the most common genetic risk factor for venous thromboembolism. Individuals with this mutation have a 3-8 times higher risk of developing deep vein thrombosis compared to the unaffected population.<sup>19,20</sup> In breast augmentation surgery, some surgeons routinely use compression devices, but there is no standard chemoprophylaxis defined for patients at higher risk of venous thromboembolism. Another concern is the risk of hematoma, which may be higher in breast augmentation surgery performed under chemoprophylaxis. Hematoma is theoretically a risk factor for the development of capsular contracture.<sup>21,22</sup> Approximately one-third of the participants (35.2%) do not perform augmentation on patients with heterozygous factor V Leiden mutation, while the majority of the remaining participants perform the procedure using compression devices and chemoprophylaxis measures.

A small portion of the participants use an insertion funnel. Surgeons who do not use a funnel consider it costly and unnecessary. The use of a funnel is thought to reduce skin contact and bacterial contamination of the implant, thereby reducing the development of capsular contracture.<sup>11,14,22-25</sup> Additionally, publications report that funnel use allows for a shorter incision for implant placement, reduces the time required for placing the implant into the pocket, facilitates the placement of larger volume implants, and reduces gel fracture.<sup>11,14,26</sup> The authors considered it an interesting finding that funnel use, which has many suggested advantages, is so low.

It is observed that surgeons who use adhesive plastic sheeting for covering the nipple-areola complex do not prioritize covering the skin around the incision. Despite the skin around the incision posing a significant bacteriological risk, approximately 80% of the survey participants do not cover the incision area.

Most surgeons prefer inframammary incisions and partial submuscular implant pockets. The choice of incision may be influenced by the lower preference for periareolar incision due to the increased bacteriological risk and higher rates of capsular contracture than inframammary incision.<sup>5,11,21,23,27,28</sup>

Only 7 percent of the participants use saline implants, and there are no surgeons who use only saline implants. The use of textured implants is predominant, with only 22% of the participants using smoothsurfaced implants either exclusively or mostly.

In 2002, Tebbetts first described the "TEPID System," the first tissue-based method, and a few years later, Tebbetts and Adams reported the "High Five System" in 2006.<sup>29,30</sup> Tissue-based systems are based on examining the patient's existing breast tissue and anatomy. Among the participants, the most commonly used methods for preoperative sizing are mathematical measurements and tissue-based methods.

Some controversial topics in breast augmentation were examined in the survey, including the role of postoperative antibiotics, the use of pharmacological agents for capsular contracture, other non-surgical methods for managing capsular contracture, and postoperative massage. Infection is a relatively rare complication after breast augmentation surgery. Various prophylactic methods are used to prevent infection.<sup>5,14,31,32</sup> Perioperative intravenous antibiotics and intraoperative antibiotic irrigation are applied by the majority of the participants. Approximately half of the participants (48.8%) recommend postoperative oral antibiotics.

There are many non-surgical approaches for treating capsular contracture. Eighty-five percent of the survey participants do not use pharmacological agents in the treatment of capsular contracture. The majority of surgeons who use pharmacological agents do so only at the initial signs of capsular contracture. It is noteworthy that the most commonly used method in the non-surgical treatment of capsular contracture among participants is massage.

The most common reason for reoperation among participants is size change. Size change is a more easily preventable cause for reoperation. A detailed preoperative assessment, effective patient-surgeon communication, and multiple consultations with the patient can significantly reduce the need for reoperation due to size change.

In the surgical management of first-time capsular contracture, most participants consider capsulectomy sufficient. Capsulectomy is clinically divided into anterior and total. The majority of participants favor total capsulectomy. Anterior capsulectomy is prone to complications such as devascularization and damage to the skin flap, while total capsulectomy carries additional risks such as pneumothorax and visceral injury.<sup>33</sup>

In the management of recurrent capsular contracture, total capsulectomy remains the mainstay of treatment, with new pocket creation, acellular dermal matrix use, and combinations of these methods also being employed. The most commonly preferred methods among participants are total capsulectomy and new pocket creation, followed by implant removal. In managing implant malposition, particularly double-bubble and bottoming-out, participants frequently perform inframammary fold reconstruction.

# CONCLUSION

This study revealed that there is a common trend toward more frequent use of inframammary incisions, silicone as the filling material, textured surfaces, and implant volumes larger than 275 cc in Türkiye. However, there is no general agreement among participants on the use of autologous fat grafting in primary breast augmentation, the non-surgical and medical management of capsular contracture, the role of three-dimensional imaging, and the management of capsular contracture. The authors believe that longterm complications may vary due to different preferences among countries.

The current attitudes of plastic surgeons in Türkiye toward breast augmentation have been evaluated with a participation rate of 18.3%, which is lower compared to the rates reported in the literature. Approximately 60% of the participants are surgeons with less than 15 years of experience. A homogeneous distribution based on clinical experience could not be achieved in our survey study. Since communication with surgeons was conducted through mailing groups, it is unclear to what extent the participating surgeons accurately represent the group with similar clinical experience. Ensuring homogeneous and higher participation in future studies would lead to more generalizable results.

## Source of Finance

During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

#### **Conflict of Interest**

No conflicts of interest between the authors and / or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

### Authorship Contributions

Idea/Concept: Nurullah Gündüz, Alper Öztürk; Design: Nurullah Gündüz, Alper Öztürk; Control/Supervision: Ayhan Işık Erdal, Serhat Şibar; Data Collection and/or Processing: Nurullah Gündüz, Alper Öztürk; Analysis and/or Interpretation: Nurullah Gündüz, Ayhan Işık Erdal, Serhat Şibar; Literature Review: Nurullah Gündüz, Alper Öztürk; Writing the Article: Nurullah Gündüz, Alper Öztürk, Ayhan Işık Erdal, Serhat Şibar; Critical Review: Nurullah Gündüz, Alper Öztürk, Ayhan Işık Erdal, Serhat Şibar; References and Fundings: Nurullah Gündüz, Alper Öztürk, Ayhan Işık Erdal, Serhat Şibar; Muterials: Nurullah Gündüz, Alper Öztürk, Ayhan Işık Erdal, Serhat Şibar; Nurullah

## REFERENCES

- Pelosi MA 3rd, Pelosi MA 2nd. Breast augmentation. Obstet Gynecol Clin North Am. 2010;37(4):533-46, viii. [Crossref] [PubMed]
- Reichenberger MA, Biedermann N, Germann G. Ästhetische mammaaugmentation [Aesthetic breast augmentation]. Chirurg. 2011;82(9):782-8. German. [Crossref] [PubMed]
- Czerny V. Plastischer Ersatz der Brusthuse durch ein Lipoma. Zentralbl Chir. 1895;27:72. [Link]
- Cronin TD, Gerow FJ. Augmentation mammaplasty: a new natural feel prosthesis. Transactions of the Third International Congress of Plastic Surgery; Washington, DC; October 13-18, 1963. 1964 Amsterdam, The Netherlands Excerpta Medica [Link]
- Adams WP Jr, Mallucci P. Breast augmentation. Plast Reconstr Surg. 2012;130(4):597e-611e. [Crossref] [PubMed]
- Stivala A, Libra M, Stivala F, Perrotta R. Breast cancer risk in women treated with augmentation mammoplasty (review). Oncol Rep. 2012;28(1):3-7. [Crossref] [PubMed]
- Denney BD, Cohn AB, Bosworth JW, Kumbla PA. Revision breast augmentation. Semin Plast Surg. 2021;35(2):98-109. [Crossref] [PubMed] [PMC]
- Epstein MD, Scheflan M. Three-dimensional imaging and simulation in breast augmentation: what is the current state of the art? Clin Plast Surg. 2015;42(4):437-50. [Crossref] [PubMed]
- Maxwell GP, Gabriel A. Acellular dermal matrix for reoperative breast augmentation. Plast Reconstr Surg. 2014;134(5):932-8. [Crossref] [PubMed]
- Li FC, Chen B, Cheng L. Breast augmentation with autologous fat injection: a report of 105 cases. Ann Plast Surg. 2014;73 Suppl 1(Suppl 1):S37-42. [Crossref] [PubMed] [PMC]
- Morkuzu S, Ozdemir M, Leach GA, Kanapathy M, Mosahebi A, Reid CM. Keller funnel efficacy in "no touch" breast augmentation and reconstruction: a systematic review. Plast Reconstr Surg Glob Open. 2022;10(11):e4676. [PubMed] [PMC]
- Hidalgo DA, Sinno S. Current trends and controversies in breast augmentation. Plast Reconstr Surg. 2016;137(4):1142-50. [Crossref] [PubMed]
- Chang EI, Hammond DC. Clinical results on innovation in breast implant design. Plast Reconstr Surg. 2018;142(4S The Science of Breast Implants):31S-38S. [Crossref] [PubMed]
- Wan D, Rohrich RJ. Modern primary breast augmentation: best recommendations for best results. Plast Reconstr Surg. 2018;142(6):933e-946e. [Crossref] [PubMed]
- Hedén P, Montemurro P, Adams WP Jr, Germann G, Scheflan M, Maxwell GP. Anatomical and round breast implants: how to select and indications for use. Plast Reconstr Surg. 2015;136(2):263-72. [Crossref] [PubMed]
- Cheng F, Cen Y, Liu C, Liu R, Pan C, Dai S. Round versus anatomical implants in primary cosmetic breast augmentation: a meta-analysis and systematic review. Plast Reconstr Surg. 2019;143(3):711-21. [Crossref] [PubMed]
- Santanelli di Pompeo F, Sorotos M, Clemens MW, Firmani G; European Association of Plastic Surgeons (EURAPS) Committee on Device Safety and Development. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): review of epidemiology and prevalence assessment in Europe. Aesthet Surg J. 2021;41(9):1014-25. [Crossref] [PubMed]

- Rosing JH, Wong G, Wong MS, Sahar D, Stevenson TR, Pu LL. Autologous fat grafting for primary breast augmentation: a systematic review. Aesthetic Plast Surg. 2011;35(5):882-90. [Crossref] [PubMed]
- 19. Lee A. Factor V Leiden. Nursing. 2014;44(6):10-2. [Crossref] [PubMed]
- Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1-16. [Crossref] [PubMed]
- Calobrace MB, Stevens WG, Capizzi PJ, Cohen R, Godinez T, Beckstrand M. Risk factor analysis for capsular contracture: a 10-year sientra study using round, smooth, and textured implants for breast augmentation. Plast Reconstr Surg. 2018;141(4S Sientra Shaped and Round Cohesive Gel Implants):20S-28S. [Crossref] [PubMed]
- Araco A, Caruso R, Araco F, Overton J, Gravante G. Capsular contractures: a systematic review. Plast Reconstr Surg. 2009;124(6):1808-19. [Crossref] [PubMed]
- Chong SJ, Deva AK. Understanding the etiology and prevention of capsular contracture: translating science into practice. Clin Plast Surg. 2015;42(4):427-36. [Crossref] [PubMed]
- Newman AN, Davison SP. Effect of Keller Funnel on the rate of capsular contracture in periareolar breast augmentation. Plast Reconstr Surg Glob Open. 2018;6(6):e1834. [Crossref] [PubMed] [PMC]
- Moyer HR, Ghazi B, Saunders N, Losken A. Contamination in smooth gel breast implant placement: testing a funnel versus digital insertion technique in a cadaver model. Aesthet Surg J. 2012;32(2):194-9. [Crossref] [PubMed]
- Montemurro P, Fischer S, Schyllander S, Mallucci P, Hedén P. Implant insertion time and incision length in breast augmentation surgery with the Keller Funnel: results from a comparative study. Aesthetic Plast Surg. 2019;43(4):881-9. [Crossref] [PubMed]
- Jacobson JM, Gatti ME, Schaffner AD, Hill LM, Spear SL. Effect of incision choice on outcomes in primary breast augmentation. Aesthet Surg J. 2012;32(4):456-62. [PubMed]
- Swanson E. Incision and capsular contracture risk: is there a relationship in breast augmentation and augmentation/mastopexy? Ann Plast Surg. 2023;90(4):389-91. [Crossref] [PubMed] [PMC]
- Tebbetts JB. A system for breast implant selection based on patient tissue characteristics and implant-soft tissue dynamics. Plast Reconstr Surg. 2002;109(4):1396-409; discussion 1410-5. [Crossref] [PubMed]
- Tebbetts JB, Adams WP. Five critical decisions in breast augmentation using five measurements in 5 minutes: the high five decision support process. Plast Reconstr Surg. 2005;116(7):2005-16. [Crossref] [PubMed]
- Samargandi OA, Joukhadar N, Al Youha S, Thoma A, Williams J. Antibiotic irrigation of pocket for implant-based breast augmentation to prevent capsular contracture: a systematic review. Plast Surg (Oakv). 2018;26(2):110-9. [Crossref] [PubMed] [PMC]
- Barr SP, Topps AR, Barnes NL, Henderson J, Hignett S, Teasdale RL, et al; Northwest Breast Surgical Research Collaborative. Infection prevention in breast implant surgery-a review of the surgical evidence, guidelines and a checklist. Eur J Surg Oncol. 2016;42(5):591-603. [Crossref] [PubMed]
- Young VL. Guidelines and indications for breast implant capsulectomy. Plast Reconstr Surg. 1998;102(3):884-91; discussion 892-4. [Crossref] [PubMed]